Document is current
Any future updates will be listed below
-
Authors
Nelson, Barbara S.
Lin, Lin
Kremer, Daniel M.
Sousa, Cristovão M.
Cotta-Ramusino, Cecilia
Myers, Amy
Ramos, Johanna
Gao, Tina
Kovalenko, Ilya
Wilder-Romans, Kari
Dresser, Joseph
Davis, Mary
Lee, Ho-Joon
Nwosu, Zeribe C.
Campit, Scott
Mashadova, Oksana
Nicolay, Brandon N.
Tolstyka, Zachary P.
Halbrook, Christopher J.
Chandrasekaran, Sriram
Asara, John M.
Crawford, Howard C.
Cantley, Lewis C.
Kimmelman, Alec C.
Wahl, Daniel R.
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
-
Funding
Funding for this research was provided by:
National Cancer Institute (T32CA009676, T32CA009676, F32CA228328, 2P01CA120964, 2P01CA120964, R35-CA197588, P30CA046592, P30CA046592, P30CA046592, U01 CA224145, U01 CA224145)
niddk (T32DK094775)
gaann (N/A)
Sky Foundation (N/A)
American Association for Cancer Research (13-70-25-LYSS)
Damon Runyon Cancer Research Foundation (DFS-09-14)
V Foundation for Cancer Research (V2016-009)
Sidney Kimmel Foundation for Cancer Research (SKF-16-005)
American Association for Cancer Research (17-20-01-LYSS)
American Cancer Society (RSG-18-186-01)
National Institutes of Health (DK097153)
- License Information
-
More Information
Article History
Received: 4 October 2019
Accepted: 20 November 2019
First Online: 2 January 2020
Ethics approval and consent to participate
: N/A
: N/A
: CAL, ACK, and LCC are inventors on patents pertaining to Kras-regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting GOT1 as a therapeutic approach. ACK also holds a patent on the autophagic control of iron metabolism and is on the SAB and has ownership interests in Cornerstone Pharmaceuticals and Vescor Therapeutics. LCC owns equity in, receives compensation from, and serves on the Scientific Advisory Boards of Agios Pharmaceuticals and Petra Pharmaceuticals. LCC’s laboratory also receives financial support from Petra Pharmaceuticals. BNN owns equity and retains compensation at Agios Pharmaceuticals. Agios Pharmaceuticals is identifying metabolic pathways of cancer cells and developing drugs to inhibit such enzymes to disrupt tumor cell growth and survival. All other authors declare that they have no competing interests.
